This year ILCA has enriched its scientific programme for the annual conference with the primary focus on NASH-related HCC and the latest advanced spatial omics technology for a better understanding of the tumour microenvironment and management of HCC in the new era.

The ILCA AC 2023 program includes the most relevant topics in the field of liver cancer, both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), from bench-based basic and translational research to bedside clinical management, including up-to-date approaches to early detection and novel therapeutic options. Sessions will cover recent advances in screening, diagnosis, and treatment, including surgery, locoregional therapies, and systemic immunotherapy and targeted agents for HCC and CCA.

Experts are invited for in-depth presentations and thought-provoking discussions to enhance their knowledge and perspective on these current and very important topics in the field. Sessions will be highly interactive with plenty of room for discussion about open issues and future perspectives for patients with liver cancer. It will be an event-provoking paradigm shift in your clinical practice or research that is not to be missed.

More information: https://ilcalive.org/annual2023/